TY - JOUR
T1 - Targeting driver mutations in lung cancer with interstitial pneumonia
T2 - A nationwide study in Japan
AU - Ikeda, Satoshi
AU - Ogura, Takashi
AU - Misumi, Toshihiro
AU - Nishioka, Yasuhiko
AU - Hashimoto, Seishu
AU - Ichikado, Kazuya
AU - Fukuizumi, Aya
AU - Takata, Saori
AU - Itoh, Taku
AU - Sato, Yuki
AU - Okishio, Kyoichi
AU - Yatera, Kazuhiro
AU - Sakamoto, Noriho
AU - Kato, Motoyasu
AU - Kikuchi, Ryota
AU - Honda, Takayuki
AU - Hashimoto, Naozumi
AU - Murakami, Koji
AU - Isshiki, Takuma
AU - Yamane, Mayuka
AU - Karayama, Masato
AU - Miyamoto, Atsushi
AU - Ishida, Yuriko
AU - Inomata, Minehiko
AU - Nishikiori, Hirotaka
AU - Yamaguchi, Kakuhiro
AU - Amimoto, Hisanori
AU - Tamura, Kentaro
AU - Yanagihara, Toyoshi
AU - Tanino, Yoshinori
AU - Koyama, Junji
AU - Tsurumaki, Nozomu
AU - Waseda, Yuko
AU - Kishaba, Tomoo
AU - Ozasa, Hiroaki
AU - Matsumoto, Masaru
AU - Kinoshita, Yoshiaki
AU - Nakamura, Yutaro
AU - Yamauchi, Hiroyoshi
AU - Kishi, Kazuma
N1 - Publisher Copyright:
© 2026 Elsevier Ltd.
PY - 2026/2/25
Y1 - 2026/2/25
N2 - Introduction Non-small cell lung cancer (NSCLC) patients with comorbid interstitial pneumonia (IP) are at high risk for drug-induced pneumonitis, and previous reports suggest a lower frequency of common driver mutations such as EGFR . This may discourage genetic testing, potentially overlooking prevalent, targetable mutations like KRAS , BRAF , and MET . This study aimed to elucidate the real-world status of genetic testing, the frequency of oncogenic drivers, and the safety and efficacy of targeted therapies in patients with NSCLC and comorbid IP. Methods This multicenter, retrospective study analyzed 1256 patients with advanced or recurrent NSCLC and comorbid chronic fibrosing IP from 37 Japanese institutions (Registry number: UMIN000055609). Results The rate of any genetic testing was 59.2 % (95 % confidence interval [CI], 56.5–62.0), with multigene testing performed in only 41.0 % (95 %CI, 38.3–43.8). Among patients with NSCLC undergoing multigene testing (N = 515), the most frequent mutations were KRAS (4.7 %; G12C, 1.9 %), followed by EGFR (2.9 %), BRAF V600E (1.6 %), and MET exon 14 skipping (1.6 %). The incidence of drug-induced pneumonitis was 0 % (0/6) for sotorasib, 50 % (4/8) for osimertinib, 33 % (1/3) for alectinib, and 25 % (1/4) for both dabrafenib plus trametinib and tepotinib. Patients with actionable oncogenic drivers receiving targeted therapy had the longest overall survival, followed by those not receiving it, and then driver-negative/unknown patients (median: 39.2, 24.0, and 13.8 months, respectively). Conclusions Multigene testing is underutilized in this population. While many targeted therapies carry a high risk of pneumonitis, sotorasib appeared relatively safe. Despite the risks, identifying and treating actionable oncogenic drivers may improve survival.
AB - Introduction Non-small cell lung cancer (NSCLC) patients with comorbid interstitial pneumonia (IP) are at high risk for drug-induced pneumonitis, and previous reports suggest a lower frequency of common driver mutations such as EGFR . This may discourage genetic testing, potentially overlooking prevalent, targetable mutations like KRAS , BRAF , and MET . This study aimed to elucidate the real-world status of genetic testing, the frequency of oncogenic drivers, and the safety and efficacy of targeted therapies in patients with NSCLC and comorbid IP. Methods This multicenter, retrospective study analyzed 1256 patients with advanced or recurrent NSCLC and comorbid chronic fibrosing IP from 37 Japanese institutions (Registry number: UMIN000055609). Results The rate of any genetic testing was 59.2 % (95 % confidence interval [CI], 56.5–62.0), with multigene testing performed in only 41.0 % (95 %CI, 38.3–43.8). Among patients with NSCLC undergoing multigene testing (N = 515), the most frequent mutations were KRAS (4.7 %; G12C, 1.9 %), followed by EGFR (2.9 %), BRAF V600E (1.6 %), and MET exon 14 skipping (1.6 %). The incidence of drug-induced pneumonitis was 0 % (0/6) for sotorasib, 50 % (4/8) for osimertinib, 33 % (1/3) for alectinib, and 25 % (1/4) for both dabrafenib plus trametinib and tepotinib. Patients with actionable oncogenic drivers receiving targeted therapy had the longest overall survival, followed by those not receiving it, and then driver-negative/unknown patients (median: 39.2, 24.0, and 13.8 months, respectively). Conclusions Multigene testing is underutilized in this population. While many targeted therapies carry a high risk of pneumonitis, sotorasib appeared relatively safe. Despite the risks, identifying and treating actionable oncogenic drivers may improve survival.
KW - Driver mutation
KW - Interstitial pneumonia
KW - Multigene testing
KW - Non-small cell lung cancer
UR - https://www.scopus.com/pages/publications/105027526049
UR - https://www.scopus.com/pages/publications/105027526049#tab=citedBy
U2 - 10.1016/j.ejca.2026.116232
DO - 10.1016/j.ejca.2026.116232
M3 - Article
C2 - 41539179
AN - SCOPUS:105027526049
SN - 0959-8049
VL - 235
JO - European Journal of Cancer
JF - European Journal of Cancer
M1 - 116232
ER -